Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Timing Is Not Everything: Reassessing Chrono-Immunotherapy in Clinical Practice.

JCO oncology practice·2026

Same author

Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes.

Advanced materials (Deerfield Beach, Fla.)·2026

Same author

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

Cancer research communications·2025

Same author

NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.

Journal of immunology (Baltimore, Md. : 1950)·2025

Same author

mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.

Journal for immunotherapy of cancer·2025

Same author

Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.

Nature communications·2024

Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 1, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive Cell Therapy for Nonhematologic Solid Tumors.

Daniel J Olson^1,2, Kunle Odunsi^2,3

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|April 27, 2023

Summary

This summary is machine-generated.

Adoptive cell therapy (ACT) shows promise for solid tumors where immunotherapy has failed. Advances in cell engineering and antigen identification are key to overcoming challenges and expanding ACT benefits for more patients.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Aug 1, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Cancer Immunology
Cellular Therapy
Oncology

Background:

Immunotherapy benefits are limited in most nonhematologic solid tumors.
Adoptive cell therapy (ACT) involves isolating and engineering immune cells for cancer treatment.
Early clinical advances show ACT's potential in difficult-to-treat solid tumors.

Purpose of the Study:

To review major forms of Adoptive Cell Therapy (ACT).
To highlight successes of ACT in solid tumors.
To discuss strategies for overcoming current ACT limitations.

Main Methods:

Review of tumor-infiltrating lymphocyte therapy.
Analysis of engineered T-cell receptor and chimeric antigen receptor T-cell therapies.
Exploration of non-T-cell therapies like natural killer-cell therapy.

Main Results:

ACT, including tumor-infiltrating lymphocytes, shows activity in melanoma and cervical cancers.
Engineered T-cell therapies demonstrate potential against poorly immunogenic solid tumors.
Non-T-cell therapies may enable allogeneic forms of ACT.

Conclusions:

ACT offers potential for long-lasting responses in advanced nonhematologic solid tumors.
Key challenges include manufacturing, antigen identification, and toxicity.
Continued advancements in cancer immunology and cell engineering are crucial for expanding ACT's reach.